131 related articles for article (PubMed ID: 38212512)
1. Retrospective case-control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer.
Watanabe K; Igarashi T; Uchiyama M; Ishigaki T; Ojiri H
Jpn J Radiol; 2024 Apr; 42(4):391-397. PubMed ID: 38212512
[TBL] [Abstract][Full Text] [Related]
2. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
Watanabe K; Igarashi T; Uchiyama M; Ojiri H
Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
[TBL] [Abstract][Full Text] [Related]
3. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
4. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
[TBL] [Abstract][Full Text] [Related]
7. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
8. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
9. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of adjuvant radioactive iodine after reoperation in patients with persistent or recurrent differentiated thyroid cancer: a systematic review.
Raghupathy J; Tan BKJ; Song HJJMD; Chia AZQ; Tan YZ; Yang SP; Parameswaran R
Langenbecks Arch Surg; 2023 Jan; 408(1):21. PubMed ID: 36635455
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
12. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
14. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
[TBL] [Abstract][Full Text] [Related]
15. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
16. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
17. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
18. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
19. Recurrence-free survival and prognosis after adjuvant therapy with radioactive iodine-131 in patients with differentiated thyroid carcinoma.
Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakashima R; Nakamura K; Mizowaki T
Sci Rep; 2023 Jul; 13(1):10795. PubMed ID: 37402838
[TBL] [Abstract][Full Text] [Related]
20. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
[Next] [New Search]